Ulcerative Colitis Latest Advances

The predictive value of intestinal ultrasound for treatment response in inflammatory bowel disease: a systematic review and pooled data analysis.

Journal: Journal of Crohn's & colitis

Published: April 15, 2026

Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.

Journal: Journal of Crohn's & colitis

Published: April 14, 2026

Ophiopogon japonicus Polysaccharides Promote Microbial Production Of Chenodeoxycholic Acid To Alleviate Ulcerative Colitis in Mice by Inhibiting the STING1-Related NF-κB Pathway.

Journal: Journal of agricultural and food chemistry

Published: April 14, 2026

Advances in clinical management of acute severe ulcerative colitis

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Published: April 13, 2026

Mapping adaptive immune responses toward fungal antigens in inflammatory bowel disease using T cell repertoire sequencing and phage-immunoprecipitation sequencing.

Journal: Journal of Crohn's & colitis

Published: April 13, 2026

Correction to: DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study.

Journal: Journal of Crohn's & colitis

Published: April 11, 2026

Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study.

Journal: Journal of Crohn's & colitis

Published: April 11, 2026

Ulcerative Colitis-Associated Neoplasia.

Journal: Diseases of the colon and rectum

Published: April 10, 2026

Linking Genetic Risk to Disease-Relevant Cellular States via Metacell-Informed Modeling with ICePop.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Correction: METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-κB pathway.

Journal: Journal of gastroenterology

Published: April 10, 2026

Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).

Journal: Journal of gastroenterology

Published: April 10, 2026

Attomolar fecal cytokine profiling reveals gut immune dynamics and disease states.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Ulcerative Colitis Latest Advances

Find the Latest Research About Ulcerative Colitis

The predictive value of intestinal ultrasound for treatment response in inflammatory bowel disease: a systematic review and pooled data analysis.

The predictive value of intestinal ultrasound for treatment response in inflammatory bowel disease: a systematic review and pooled data analysis.

Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.

Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.

Ophiopogon japonicus Polysaccharides Promote Microbial Production Of Chenodeoxycholic Acid To Alleviate Ulcerative Colitis in Mice by Inhibiting the STING1-Related NF-κB Pathway.

Ophiopogon japonicus Polysaccharides Promote Microbial Production Of Chenodeoxycholic Acid To Alleviate Ulcerative Colitis in Mice by Inhibiting the STING1-Related NF-κB Pathway.

Advances in clinical management of acute severe ulcerative colitis

Advances in clinical management of acute severe ulcerative colitis

Mapping adaptive immune responses toward fungal antigens in inflammatory bowel disease using T cell repertoire sequencing and phage-immunoprecipitation sequencing.

Mapping adaptive immune responses toward fungal antigens in inflammatory bowel disease using T cell repertoire sequencing and phage-immunoprecipitation sequencing.

Correction to: DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study.

Correction to: DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study.

Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study.

Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study.

Ulcerative Colitis-Associated Neoplasia.

Ulcerative Colitis-Associated Neoplasia.

Linking Genetic Risk to Disease-Relevant Cellular States via Metacell-Informed Modeling with ICePop.

Linking Genetic Risk to Disease-Relevant Cellular States via Metacell-Informed Modeling with ICePop.

Correction: METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-κB pathway.

Correction: METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-κB pathway.

Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).

Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).

Attomolar fecal cytokine profiling reveals gut immune dynamics and disease states.

Attomolar fecal cytokine profiling reveals gut immune dynamics and disease states.